This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolff, A. C. Articles by Davidson, N. E. Search for Related Content PubMed PubMed Citation Articles by Wolff, A. C. Articles by Davidson, N. E.

Primary Systemic Therapy in Operable Breast Cancer

From The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD.

Address reprint requests to Antonio C. Wolff, MD, The Johns Hopkins Oncology Center, Cancer Research Building, Room 189, 1650 Orleans St, Baltimore, MD 21231-1000; email awolff{at}jhmi.edu

ABSTRACT

PURPOSE: Laboratory studies suggest that primary systemic therapy (PST) could improve control of micrometastatic disease and impact on overall survival (OS). This article examines the rationale for and preclinical and clinical data of PST in operable breast cancer and the potential role of intermediate biomarkers as predictive and/or prognostic factors for response and survival.

DESIGN AND METHOD: We conducted an extensive literative review (including MEDLINE) on preclinical studies, single-arm feasibility studies, large randomized single- and multi-institutional trials, and laboratory correlate studies of PST in breast cancer.

RESULTS: Small trials in locally advanced disease showed high initial rates of response and local control. Six randomized clinical trials (RCTs) of PST for palpable, operable breast cancer have been reported since 1991 (from 204 to 1,523 patients each). These data clearly show a small but significant (less than 10%) absolute increase in the use of breast-conservation treatment (BCT) with similar rates of local control. Although one study showed better disease-free survival (DFS) and another showed better OS, most studies did not show any survival advantage of primary versus adjuvant systemic therapy. Thus far, pathologic complete response seems to be the best predictor of survival, but clinical response assessment correlates poorly with pathologic response. Pilot studies demonstrated feasibility of procuring tissue at diagnosis and after treatment for assays of potential intermediate biomarkers. Initial data suggest a potential correlation between markers of proliferation and apoptosis and in vivo chemotherapy sensitivity.

CONCLUSION: Thus far, RCTs of PST versus standard adjuvant therapy have not shown any clear benefit for DFS or OS in early breast cancer. Ongoing trials should determine if specific subsets of patients at risk would benefit from additional systemic therapy and the potential role of intermediate biomarkers in identifying such women. Although PST results in a small increase in the rate of BCT with similar rates of local control, current PST strategies should not replace standard adjuvant approaches. Rather, they represent an acceptable alternative to women with palpable, operable tumors and an excellent arena for clinical trials.

NOTES

This article is based on a Plenary Lecture presented by N.E.D. at the Twenty-First Annual San Antonio Breast Cancer Symposium, December 15, 1998, San Antonio, TX.

This article has been cited by other articles:

				A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al. Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813. [Abstract] [Full Text] [PDF]

				C Natoli, E Cianchetti, N Tinari, D Angelucci, A Grassadonia, M Zilli, C Ficorella, E Ricevuto, S Grossi, M De Tursi, et al. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer Ann. Onc., June 1, 2007; 18(6): 1015 - 1020. [Abstract] [Full Text] [PDF]

				M. A. A. Koike Folgueira, D. M. Carraro, H. Brentani, D. F. da Costa Patrao, E. M. Barbosa, M. M. Netto, J. R. F. Caldeira, M. L. H. Katayama, F. A. Soares, C. T. Oliveira, et al. Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7434 - 7443. [Abstract] [Full Text] [PDF]

				N. E. Davidson and M. Morrow Sometimes a Great Notion--An Assessment of Neoadjuvant Systemic Therapy for Breast Cancer J Natl Cancer Inst, February 2, 2005; 97(3): 159 - 161. [Full Text] [PDF]

				T. Shenkier, L. Weir, M. Levine, I. Olivotto, T. Whelan, and L. Reyno Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer Can. Med. Assoc. J., March 16, 2004; 170(6): 983 - 994. [Abstract] [Full Text] [PDF]

				L. A. Newman, N. L. Pernick, V. Adsay, K. A. Carolin, P. I. Philip, S. Sipierski, D. L. Bouwman, M. A. Kosir, M. White, and D. W. Visscher Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated With Preoperative Chemotherapy Correlates With Breast Cancer Outcome Ann. Surg. Oncol., August 1, 2003; 10(7): 734 - 739. [Abstract] [Full Text] [PDF]

				H. J. Burstein, L. N. Harris, R. Gelman, S. C. Lester, R. A. Nunes, C. M. Kaelin, L. M. Parker, L. W. Ellisen, I. Kuter, M. A. Gadd, et al. Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study J. Clin. Oncol., January 1, 2003; 21(1): 46 - 53. [Abstract] [Full Text] [PDF]

				V. Stearns, B. Singh, T. Tsangaris, J. G. Crawford, A. Novielli, M. J. Ellis, C. Isaacs, M. Pennanen, C. Tibery, A. Farhad, et al. A Prospective Randomized Pilot Study to Evaluate Predictors of Response in Serial Core Biopsies to Single Agent Neoadjuvant Doxorubicin or Paclitaxel for Patients with Locally Advanced Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 124 - 133. [Abstract] [Full Text] [PDF]

				P O Chappuis, J Goffin, N Wong, C Perret, P Ghadirian, P N Tonin, and W D Foulkes A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer J. Med. Genet., August 1, 2002; 39(8): 608 - 610. [Full Text] [PDF]

				M. Parton, S. Krajewski, I. Smith, M. Krajewska, C. Archer, M. Naito, R. Ahern, J. Reed, and M. Dowsett Coordinate Expression of Apoptosis-associated Proteins in Human Breast Cancer before and during Chemotherapy Clin. Cancer Res., July 1, 2002; 8(7): 2100 - 2108. [Abstract] [Full Text] [PDF]

				L. A. Newman, A. U. Buzdar, S. E. Singletary, H. M. Kuerer, T. Buchholz, F. C. Ames, M. I. Ross, and K. K. Hunt A Prospective Trial of Preoperative Chemotherapy in Resectable Breast Cancer: Predictors of Breast-Conservation Therapy Feasibility Ann. Surg. Oncol., April 1, 2002; 9(3): 228 - 234. [Abstract] [Full Text] [PDF]

				V. Stearns, C. A. Ewing, R. Slack, M. F. Penannen, D. F. Hayes, and T. N. Tsangaris Sentinel Lymphadenectomy After Neoadjuvant Chemotherapy for Breast Cancer May Reliably Represent the Axilla Except for Inflammatory Breast Cancer Ann. Surg. Oncol., April 1, 2002; 9(3): 235 - 242. [Abstract] [Full Text] [PDF]

				G. von Minckwitz, S. D. Costa, G. Raab, J.-U. Blohmer, H. Eidtmann, J. Hilfrich, E. Merkle, C. Jackisch, G. Gademann, A. H. Tulusan, et al. Dose-Dense Doxorubicin, Docetaxel, and Granulocyte Colony-Stimulating Factor Support With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast: A Randomized, Controlled, Open Phase IIb Study J. Clin. Oncol., August 1, 2001; 19(15): 3506 - 3515. [Abstract] [Full Text] [PDF]

				M. Parton, M. Dowsett, and I. Smith Studies of apoptosis in breast cancer BMJ, June 23, 2001; 322(7301): 1528 - 1532. [Full Text] [PDF]